Mini-Symposium: Fungi and The Paediatric LungPneumocystis pneumonia in children
Introduction
Pneumocystis pneumonia (PCP) is a major cause of morbidity and mortality in children and adults with acquired immune deficiency syndrome (AIDS) and other immunosuppressive conditions. The causative agent, Pneumocystis carinii, also termed Pneumocystis jirovecii, is a eukaryotic microorganism with features superficially resembling protozoa and fungi. Phylogenetic analysis of pneumocystis 16S-like rRNA has demonstrated it to be a fungus.1
PCP was initially described as interstitial plasma cell pneumonia in the 1940 s. It was first observed in hospitals and orphanages in premature neonates and malnourished children in the 1940 s. Prior to the AIDS epidemic, Pneumocystis had been increasingly recognized as an opportunistic pathogen in children suffering from various immune compromising conditions. These include allogeneic haematopoietic stem cell transplantation (HSCT), solid organ transplantation, receipt of corticosteroids and other immunosuppressive agents, and congenital immunodeficiency syndromes. Following the introduction and widespread availability of highly active antiretroviral therapy (HAART) and the use of prophylaxis in susceptible populations, the incidence of PCP in children has declined dramatically.2 However, in the absence of appropriate prophylaxis pneumocystis continues to constitute a major threat to the health of severely immunocompromised children and adults.
Section snippets
Epidemiology
Initial exposure to Pneumocystis generally occurs during the first few months of life and sub-clinical infection in immunocompetent children is very common.3 In a cohort of healthy US children, two-thirds developed Pneumocystis antibodies by the age of 4 years.4 A complete understanding of the epidemiology of Pneumocystis continues to be hampered by the inability reliably to cultivate the organism in vitro. Infection is thought to occur following person-to-person transmission via respiratory
Pathogenesis – immune response
For infection to occur, the inhaled organism must first evade the upper respiratory tract defenses and settle in alveoli. Within alveoli, Pneumocystis trophozoites attach to respiratory epithelia, proliferate and inhibit epithelial repair processes.44 If not checked by host defense mechanisms, the infection progresses to cause severe lung damage and ultimately respiratory failure and death.
Effective host defenses against Pneumocystis are mediated by a combination of innate, T-cell mediated, and
Clinical and radiological manifestations
The most common presentation of Pneumocystis infection is pneumonia. Rarely, in highly immunocompromised patients, who do not receive systemic Pneumocystis prophylaxis, pneumocystosis may present as extrapulmonary disease with reticuloendothelial, auditory and ophthalmic involvement.63 Although PCP was originally described in the 1940 s as interstitial plasma cell pneumonia, a disease of young, malnourished children living in crowded conditions, almost all cases in the developed world and an
Prognosis and outcome
The prognosis of children with HIV-associated PCP depends upon multiple factors, including degree of hypoxaemia at presentation, need for mechanical ventilation and access to medical care (including HAART). Survival following PCP infection in HIV-infected infants in the UK and Ireland improved significantly with advances in medical care.73 This is in contrast to the situation in developing countries where PCP-associated mortality rates among children continue to be 40% or higher.74 Mortality
Diagnosis
The signs and symptoms of PCP are frequently non-specific and the organism is not cultivable. Therefore, definitive diagnosis relies on microscopic identification of Pneumocystis from specimens such as sputum, bronchoalveolar lavage (BAL) fluid and lung tissue. Typical pathology findings are alveolar foamy eosinophilic proteinaceous material in association with Pneumocystis cysts and trophozoites. Methods for detection of infection include histological visualization using Papanicolaou, Gomori's
Treatment
Various antimicrobial agents, including sulphonamides, pentamidine, dapsone, atovaquone and clindamycin, have activity against Pneumocystis. Current recommendations for treatment are summarized in Table 2. Folate antagonists, particularly trimethoprim–sulphamethoxazole (TMP–SMX), are the most commonly used agents. Pneumocystis cannot effectively import folate and must therefore synthesize this molecule de novo.87, 88 Trimethoprim and sulphamethoxazole impair dihydrofolate reductase and
Prophylaxis
The highest risk period for development of PCP in children with vertically acquired HIV is between 3 and 6 months of age.21 However, CD4 counts are an imprecise indicator of the risk for development of PCP in HIV-infected children < 1 year old.103 Children born to HIV-infected mothers should be administered prophylaxis with TMP–SMX beginning at age 6 weeks after discontinuation of neonatal zidovudine treatment, and prophylaxis should be continued through the first year of life unless the child
Practice points
- •
Pneumocystis pneumonia (PCP) occurs in immunocompromised children with quantitative and qualitative defects in T lymphocytes, especially those with lymphoid malignancies, HIV infection, and corticosteroid therapy.
- •
Diagnosis is established through direct examination by Wright-Giemsa, fluoroscent dye, fluorescent antibody, or polymerase chain reaction (PCR) from respiratory secretions.
- •
Trimethoprim–sulphamethoxazole (TMP–SMX), is used for initial therapy in most patients.
- •
Pentamidine, atovaquone,
References (109)
- et al.
Infection with Pneumocystis carinii is prevalent in healthy Gambian children
Trans R Soc Trop Med Hyg
(1990) - et al.
Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy
Mayo Clin Proc
(1996) - et al.
Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors
Am J Med
(1993) - et al.
Prevalence of Pneumocystis jiroveci pneumonia in Tunisian primary immunodeficient patients
Arch Pediatr
(2007) - et al.
Clinical course of patients with WASP gene mutations
Blood
(2004) - et al.
Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS
Chest
(1987) - et al.
Bronchoalveolar lavage as the exclusive diagnostic modality for Pneumocystis carinii pneumonia. A prospective study among patients with acquired immunodeficiency syndrome
Chest
(1986) - et al.
Role of flexible bronchoscopy in the diagnosis of pulmonary infiltrates in pediatric patients with cancer
J Pediatr
(1989) - et al.
Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia
Chest
(1995) - et al.
Serum indicators for the diagnosis of pneumocystis pneumonia
Chest
(2007)
Pancreatitis in pediatric human immunodeficiency virus infection
J Pediatr
Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi
Nature
Incidence of opportunistic and other infections in HIV-infected children in the HAART era
JAMA
Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children
Pediatrics
Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments
J Clin Microbiol
Pneumocystis jirovecii in general population
Emerg Infect Dis
Pneumocystis pneumonia
N Engl J Med
Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers
J Clin Microbiol
Natural mode of acquisition for de novo infection with Pneumocystis carinii
J Infect Dis
An outbreak of Pneumocystis carinii pneumonia in children with malignancy
J Paediatr Child Health
An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?
Clin Infect Dis
Endemic infantile Pneumocystis carinii infection: the Shiraz study
Natl Cancer Inst Monogr
Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection
Emerg Infect Dis
Pneumocystis carinii pneumonitis in young immunocompetent infants
Pediatrics
Association of primary Pneumocystis carinii infection and sudden infant death syndrome
Clin Infect Dis
Pneumocystis is not a direct cause of sudden infant death syndrome
Pediatr Infect Dis J
Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis
J Infect Dis
Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus-infected patients during one or several episodes of pneumonia
J Clin Microbiol
Current epidemiology of Pneumocystis pneumonia
Emerg Infect Dis
Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana
Pediatr Infect Dis J
Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection
JAMA
Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America
MMWR Recomm Rep
Pneumocystis carinii pneumonia in renal transplant recipients
Nephrol Dial Transplant
Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases
Arch Intern Med
Risk of infectious complications in patients taking glucocorticosteroids
Rev Infect Dis
Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004
Scand J Infect Dis
Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis
Cancer
Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome
Clin Infect Dis
Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis
Am J Hematol
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications
J Clin Oncol
Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
J Clin Oncol
Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients
Clin Infect Dis
Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis
Am J Respir Crit Care Med
Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases
J Rheumatol
Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab
Scand J Infect Dis
Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease
Inflamm Bowel Dis
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases
Dig Dis Sci
The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients
Medicine (Baltimore)
Pulmonary diseases in children with severe combined immune deficiency and DiGeorge syndrome
Pediatr Pulmonol
Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment
J Clin Invest.
Cited by (49)
Lincosamide Antibiotics
2022, Comprehensive PharmacologyFungal lung disease
2021, Paediatric Respiratory ReviewsCitation Excerpt :PCP pneumonitis may present with an insidious onset of hypoxaemia, fine crackles on chest auscultation. It has also been described in non-AIDS immunocompromised patients during the weaning of systemic steroids and the reduction of chemotherapy, and is attributed to the reconstitution of host immune function [10]. Imaging findings are similar in AIDS and non-AIDS patients.
Recent epidemiology of Pneumocystis pneumonia in Japan
2020, Journal of Infection and ChemotherapyCitation Excerpt :Our data showed that there were approximately 2300 cases of PCP patients annually in Japan. In recent years, non-HIV–related PCP has been increasingly reported in both adults and children because of widespread use of immunosuppressive therapy, including that used for solid organ or hematopoietic stem cell transplantation, corticosteroids, and biological products [12,13]. The information on the exact number of PCP patients at the national level is still limited due to the lack of nationwide reporting systems.
Two pediatric cases of Pneumocystis jirovecii pneumonia diagnosed by polymerase chain reaction of gastric lavage
2019, Journal of Infection and ChemotherapyCitation Excerpt :Therefore, it is difficult to evaluate cellular immunity by the number of CD4 positive T cells [10]. In non-HIV/AIDS patients, it is important to evaluate the risk of cellular immunodeficiency as a result of steroids and immunosuppressants dosage, and administration period [10]. In conclusion, when PJP is suspected in pediatric patients but symptoms are minor, intubation is not needed, and collection of lower respiratory tract specimens is difficult, PCR of gastric lavage to detect P. jirovecii can be a useful method.